OBJECTIVES: To investigate the effect of 12 weeks of strength training in combination with a nonsteroidal anti-inflammatory drug (NSAID), glucosamine, or placebo on muscle cross-sectional area (CSA), strength (primary outcome parameters), and function, power, pain, and satellite cell number (secondary outcome parameters) in patients with knee osteoarthritis (OA). DESIGN: Double-blinded, randomized controlled trial. SETTING: Hospital. PARTICIPANTS: Patients (N=36; 20 women, 16 men; age range, 50-70y) with bilateral tibiofemoral knee OA. A total of 181 patients were approached, and 145 were excluded. INTERVENTIONS: Patients were randomly assigned to treatment with the NSAID ibuprofen (n=12), glucosamine (n=12), or placebo (n=12) during 12 weeks of quadriceps muscle strength training. MAIN OUTCOME MEASURES: Muscle CSA and strength. RESULTS: No differences between groups were observed in gains in muscle CSA. Training combined with ibuprofen increased maximal isometric strength by an additional .22Nm/kg (95% confidence interval [CI], .01-.42; P=.04), maximal eccentric muscle strength by .38Nm/kg (95% CI, .05-.70; P=.02), and eccentric muscle work by .27J/kg (95% CI, .01-.53; P=.04) in comparison with placebo. Training combined with glucosamine increased maximal concentric muscle work by an additional .24J/kg versus placebo (95% CI, .06-.42; P=.01). CONCLUSIONS: In patients with knee OA, NSAID or glucosamine administration during a 12-week strength-training program did not improve muscle mass gain, but improved maximal muscle strength gain in comparison with treatment with placebo. However, we do not find that the benefits are large enough to justify taking NSAIDs or glucosamine.
RCT Entities:
OBJECTIVES: To investigate the effect of 12 weeks of strength training in combination with a nonsteroidal anti-inflammatory drug (NSAID), glucosamine, or placebo on muscle cross-sectional area (CSA), strength (primary outcome parameters), and function, power, pain, and satellite cell number (secondary outcome parameters) in patients with knee osteoarthritis (OA). DESIGN: Double-blinded, randomized controlled trial. SETTING: Hospital. PARTICIPANTS: Patients (N=36; 20 women, 16 men; age range, 50-70y) with bilateral tibiofemoral knee OA. A total of 181 patients were approached, and 145 were excluded. INTERVENTIONS:Patients were randomly assigned to treatment with the NSAID ibuprofen (n=12), glucosamine (n=12), or placebo (n=12) during 12 weeks of quadriceps muscle strength training. MAIN OUTCOME MEASURES: Muscle CSA and strength. RESULTS: No differences between groups were observed in gains in muscle CSA. Training combined with ibuprofen increased maximal isometric strength by an additional .22Nm/kg (95% confidence interval [CI], .01-.42; P=.04), maximal eccentric muscle strength by .38Nm/kg (95% CI, .05-.70; P=.02), and eccentric muscle work by .27J/kg (95% CI, .01-.53; P=.04) in comparison with placebo. Training combined with glucosamine increased maximal concentric muscle work by an additional .24J/kg versus placebo (95% CI, .06-.42; P=.01). CONCLUSIONS: In patients with knee OA, NSAID or glucosamine administration during a 12-week strength-training program did not improve muscle mass gain, but improved maximal muscle strength gain in comparison with treatment with placebo. However, we do not find that the benefits are large enough to justify taking NSAIDs or glucosamine.
Authors: Jasmijn F M Holla; Diana C Sanchez-Ramirez; Marike van der Leeden; Johannes C F Ket; Leo D Roorda; Willem F Lems; Martijn P M Steultjens; Joost Dekker Journal: J Behav Med Date: 2014-05-20
Authors: Mario Simental-Mendía; Adriana Sánchez-García; Félix Vilchez-Cavazos; Carlos A Acosta-Olivo; Víctor M Peña-Martínez; Luis E Simental-Mendía Journal: Rheumatol Int Date: 2018-06-11 Impact factor: 2.631
Authors: Ana Claudia Mattiello-Sverzut; Susanne G Petersen; Michael Kjaer; Abigail L Mackey Journal: Rheumatol Int Date: 2013-02-27 Impact factor: 2.631
Authors: Heather Greenlee; Katherine D Crew; Theresa Shao; Grace Kranwinkel; Kevin Kalinsky; Matthew Maurer; Lois Brafman; Beverly Insel; Wei Yann Tsai; Dawn L Hershman Journal: Support Care Cancer Date: 2012-11-01 Impact factor: 3.603
Authors: Jesper Knoop; Joost Dekker; Jan-Paul Klein; Marike van der Leeden; Martin van der Esch; Dick Reiding; Ramon E Voorneman; Martijn Gerritsen; Leo D Roorda; Martijn P M Steultjens; Willem F Lems Journal: Arthritis Res Ther Date: 2012-10-05 Impact factor: 5.156
Authors: Yves Henrotin; Xavier Chevalier; Gabriel Herrero-Beaumont; Timothy McAlindon; Ali Mobasheri; Karel Pavelka; Christiane Schön; Harrie Weinans; Hans Biesalski Journal: BMC Res Notes Date: 2013-03-26